Search
for
Sort by
Research 211–240 of 583
- The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- 600 Impact of baricitinib on work productivity and indirect costs in adult patients with atopic dermatitis: A meta-analysis of clinical trials
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- Clinical response to oral tofacitinib in pediatric patients with alopecia areata
- Delayed granulomatous eruption of the nose associated with ruxolitinib
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Comprehensive single-cell transcriptomic profiling of the scalp from patients with moderate-to-severe alopecia areata
- Baricitinib in Alopecia Areata: Real-Life Changes in Lipid Profile and Hematologic Inflammation Indices at 52 weeks
- Baricitinib Effectiveness in JAKi‐Naïve and Tofacitinib‐Exposed Patients: A Prospective Study in Alopecia Areata
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- P88 Real-world evidence on efficacy and safety of Janus Kinase inhibitors in the treatment of moderate to severe active Ulcerative Colitis
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Improvement in health‐related quality of life and symptoms of anxiety and depression in patients with alopecia areata randomized to baricitinib or placebo: Results from two international randomized controlled trials
- Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
- 705 Particulate matter induces inflammatory response in human outer root sheath cells via oxidative stress-dependent MAPK and JAK-STAT signaling pathways
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- JAK inhibitors in dermatology: The promise of a new drug class
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta‐analysis
- A phase 2a trial of brepocitinib for cicatricial alopecia
- Nuclear Localization of STAT5A Modified with O-Linked N-Acetylglucosamine and Early Involution in the Mammary Gland of Hirosaki Hairless Rat
- Alopecia Areata: A Review of the Role of Oxidative Stress, Possible Biomarkers, and Potential Novel Therapeutic Approaches